Please assess the completion status of the following clinical trial:

Trial Title: Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women aged 45+~* postmenopausal~* osteoporotic with high risk of fracture~Exclusion Criteria:~* no significant previous use of bone health modifying treatments

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard dose teriparatide (Type: ACTIVE_COMPARATOR): teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
- High dose teriparatide (Type: ACTIVE_COMPARATOR): teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15

Based on this trial design, predict the completion outcome and termination type (if applicable).